What does the research say about Cardiac amyloidosis?

Q: What does the research say about Cardiac amyloidosis?

The scientific consensus on Cardiac amyloidosis is emerging. Emerging evidence with 100 primary claims Based on 100 analyzed claims: 0 agreements and 0 contradictions.

Cardiac amyloidosis — Research & Evidence

New research on Cardiac amyloidosis

Enhanced Expression of Type 1 Helper T-Cell Cytokines in the Myocardium of Active Cardiac Sarcoidosis

Circulation Journal — Terasaki F — Jan 2008

Marked HDL deficiency and premature coronary heart disease

Current Opinion in Lipidology — Schaefer E — Jul 2010

Improved diagnosis of idiopathic giant cell myocarditis and cardiac sarcoidosis by myocardial gene expression profiling

European Heart Journal — Laßner D — Mar 2014

Widespread cardiovascular autonomic dysfunction in primary amyloidosis: does spontaneous hyperventilation have a compensatory role against postural hypotension?

Heart — Bernardi L — Nov 2002

Cell Therapy Improves Cardiac Function in Anthracycline-Induced Cardiomyopathy Preclinical Models: A Systematic Review and Meta-Analysis

Stem Cells and Development — Lopes G — Aug 2020

Genetics of inherited cardiomyopathies

Expert Review of Cardiovascular Therapy — Bowles K — Sep 2004

Are Interactions between Epicardial Adipose Tissue, Cardiac Fibroblasts and Cardiac Myocytes Instrumental in Atrial Fibrosis and Atrial Fibrillation?

Cells — Krishnan A — Sep 2021

Nucleolar Organizer Regions in Cardiac Lesions Induced by Doxorubicin

Toxicologic Pathology — Leblanc B — Feb 1991

Plasminogen activator inhibitor-1 (PAI-1) is cardioprotective in mice by maintaining microvascular integrity and cardiac architecture

Blood — Xu Z — Dec 2009

Cardiac sarcoidosis presenting as an arrhythmogenic right ventricular cardiomyopathy

Heart — Barbou F — Sep 2012

Cardiac Sarcoidosis Completely Mimicking Biventricular Arrhythmogenic Cardiomyopathy

ESC Heart Failure — Vereckei A — Aug 2022

Anthracycline‐induced cardiomyopathy: long‐term effects on myocardial cell integrity, cardiac adrenergic innervation and fatty acid uptake

Clinical Physiology — Nousiainen T — Jan 2001

Evidence brief: Cardiac amyloidosis

Cardiac amyloidosis (also known as ATTR amyloidosis, cardiac amyloid, TTR amyloidosis). ATTR and AL amyloid cardiomyopathy

As of 2026-08-14, the scientific consensus on Cardiac amyloidosis is emerging. Emerging evidence with 100 primary claims Based on 100 analyzed claims across Synapse's enriched corpus, the evidence shows.

This evidence brief synthesizes Synapse's enriched cardiology corpus; cite as synapsesocial.com/topics/cardiac-amyloidosis.

Deterministic synthesis from Synapse's enriched corpus — 56 words. No AI-generated novel content; every figure is sourced from the underlying paper, guideline, or trial record linked on this page.

Cardiac amyloidosis

What the evidence says about Cardiac amyloidosis

Actively debated